Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 18/20 | 0.59 |
| ▸ | MMP13 | P45452 | 16/20 | 0.57 |
| ▸ | MMP1 | P03956 | 14/20 | 0.57 |
| ▸ | MMP9 | P14780 | 7/20 | 0.57 |
| ▸ | MMP2 | P08253 | 1/20 | 0.57 |
| ▸ | MMP7 | P09237 | 1/20 | 0.57 |
| ▸ | MMP8 | P22894 | 1/20 | 0.57 |
| ▸ | MMP3 | P08254 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3938831 | 1.00 | ADAM17 (0.59) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL3942784 | 1.00 | ADAM17 (0.59) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL3942787 | 1.00 | ADAM17 (0.59) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL4148426 | 0.98 | ADAM17 (0.59) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL7872221 | 0.89 | ADAM17 (0.52) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL7878258 | 0.89 | ADAM17 (0.52) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL7358605 | 0.89 | ADAM17 (0.52) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL7879791 | 0.87 | ADAM17 (0.52) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL3944455 | 0.80 | ADAM17 (0.57) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL3944450 | 0.80 | ADAM17 (0.57) | ADAM17MMP13MMP1MMP9MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6326516-B1 | RHEUMATIC DISEASES; SEPSIS; ANTIULCER AGENTS | AMERICAN CYANAMID COMPANY | 2001-12-04 | — | — | US | claimed |
| EP-1147078-A1 | ACETYLENIC (BETA)-SULFONAMIDO AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS | American Cyanamid Company (US) | 2001-10-24 | — | — | EP | claimed |
| WO-2000044711-A1 | ACETYLENIC $G(b)-SULFONAMIDO AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | claimed |
| US-7488754-B2 | Method for the treatment of polycystic kidney disease | WYETH (US) | 2009-02-10 | — | — | US | disclosed |
| US-20040063672-A1 | Method for the treatment of polycystic kidney disease | WYETH HOLDINGS CORPORATION | 2004-04-01 | — | — | US | disclosed |
| US-6326516-B1 | RHEUMATIC DISEASES; SEPSIS; ANTIULCER AGENTS | AMERICAN CYANAMID COMPANY | 2001-12-04 | — | — | US | disclosed |
| EP-1147078-A1 | ACETYLENIC (BETA)-SULFONAMIDO AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS | American Cyanamid Company (US) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000044711-A1 | ACETYLENIC $G(b)-SULFONAMIDO AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063672-A1 | Method for the treatment of polycystic kidney disease | PKD1, PKD2, PCSK6 | ADAM17 9/4885MMP13 246/4885MMP1 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.